Clinical Trials Directory

Trials / Unknown

UnknownNCT06171048

Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects

A Pharmacokinetics Study of CM310 Recombinant Humanized Monoclonal Antibody Injection in Healthy Subjects

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
236 (estimated)
Sponsor
Keymed Biosciences Co.Ltd · Industry
Sex
Male
Age
20 Years – 45 Years
Healthy volunteers
Accepted

Summary

This is a single-center, randomized, open-label study to evaluate the pharmacokinetics of CM310 in healthy subjects.

Detailed description

This study includes screening and treatment and follow-up periods.

Conditions

Interventions

TypeNameDescription
BIOLOGICALCM310CM310 injection

Timeline

Start date
2024-04-30
Primary completion
2025-04-30
Completion
2025-04-30
First posted
2023-12-14
Last updated
2023-12-14

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06171048. Inclusion in this directory is not an endorsement.